NCT04381364

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 98 (actual)
• Sponsor: Ola Blennow, MD, PhD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Randomized open label clinical trial carried out at study centers in Sweden, including Karolinska University Hospital, S:t Göran Hospital, Danderyd Hospital and Västmanlands Hospital. Patients with COVID-19 who are hospitalized with oxygen therapy are eligible for inclusion. Subjects are randomized to 14 days of inhalation with ciclesonide 360 µg twice daily or to standard of care. Primary outcome is duration of received supplemental oxygen therapy. Key secondary outcome is a composite outcome of death and received invasive mechanical ventilation within 30 days.

Conditions

• Covid-19
• Pneumonia, Viral
• Sars-CoV2

Interventions

Type	Name	Description
DRUG	Ciclesonide Inhalation Aerosol	Ciclesonide 320 µg twice daily for 14 days.

Timeline

• Start date: 2020-05-29
• Primary completion: 2021-08-01
• Completion: 2022-01-31
• First posted: 2020-05-08
• Last updated: 2022-02-02

Locations

11 sites across 1 country: Sweden